| Target Validation Information | |||||
|---|---|---|---|---|---|
| TTD ID | T58970 | ||||
| Target Name | Extracellular signal-regulated kinase 2 (ERK2) | ||||
| Type of Target |
Clinical trial |
||||
| Drug Potency against Target | DEBROMOHYMENIALDISINE | Drug Info | IC50 = 824 nM | [1] | |
| FR-180204 | Drug Info | IC50 = 1900 nM | [2] | ||
| Ro-4396686 | Drug Info | IC50 = 12600 nM | [3] | ||
| References | |||||
| REF 1 | Potent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine. Bioorg Med Chem Lett. 2004 Aug 16;14(16):4319-21. | ||||
| REF 2 | Crystal structure of human ERK2 complexed with a pyrazolo[3,4-c]pyridazine derivative. Bioorg Med Chem Lett. 2006 Jan 1;16(1):55-8. | ||||
| REF 3 | Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.